Clofazimina

Lampren Capsulas

100 mg cápsula blandaSpainWithdrawnAuthorised 31 Jan 1970

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Packs

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Clofazimina

Lampren Capsulas

100 mg cápsula blandaSpainWithdrawnAuthorised 31 Jan 1970

Product informationAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Packs

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Pack	Code	Status
LAMPREN CAPSULAS, 100 cápsulas	777144

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agencia Española de Medicamentos y Productos Sanitarios

Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.

Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required · Added 12 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Clofazimina
Strength: 100 mg
Dosage form: cápsula blanda
Route: vía oral
Register: Spain (AEMPS)
Status: Withdrawn
Status in the register: Revocado
Authorised: 31 Jan 1970
Registration: 48886
Marketing authorisation holder: Novartis Farmaceutica S.A.
Procedure: National, MRP or DCP
Supply: Medicamento Sujeto A Prescripción Médica. Tratamiento De Larga Duración